MOH:NYSEMolina Healthcare Inc Analysis

Molina Healthcare trades at $148.97, comfortably above its 20‑day ($141.73) and 50‑day ($143.24) SMAs but below the 200‑day SMA ($167.22), suggesting short‑term strength within a longer‑term downtrend. The stock’s PE of 16.7 is well under the industry average of 26.2, and its price‑to‑sales ratio of 0.18 signals a potentially attractive valuation, yet operating margins are negative (-1.5%) and free cash flow remains in the red (-$100 M). Volatility is elevated at 39% over the past 30 days and volume is trending lower, which adds to the short‑term risk profile. The balance sheet shows a net cash position (cash $8.26 B vs debt $4.05 B) but a debt‑to‑equity ratio near 100% and negative operating cash flow raise concerns about sustainability. Analyst consensus is neutral (hold) with a median price target of $144, slightly below the current price, while notable investors such as Seth Klarman have added the stock, contrasting with Jim Cramer’s bearish comments. Overall, the mix of undervalued multiples, modest revenue growth (7.1%), and significant cash‑flow and regulatory headwinds suggests a cautious but not dismissive stance.
Investors should watch the upcoming Q1 earnings release for clues on cash‑flow trends and policy impacts, and consider the stock’s position near the $152.45 resistance level when timing any entry or exit.